Press releases found on our website are intended as reference information for investors and journalists. The information contained in each press release was accurate at the time of issuance and caprotec™ bioanalytics GmbH assumes no responsibility for updating the information to reflect subsequent developments.

caprotec bioanalytics Awarded US Patent for CCMS Proteome Profiling Technology

Berlin, Germany, August 20, 2015 – caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,798 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

The newly granted patent titled “Capture Compounds , Collections Thereof and Methods for Analyzing the Proteome and Complex Compositions” complements the company’s patent portfolio of more than 40 issued patents in countries including the European Union, Canada, Australia, Singapore, Hong Kong, Japan, Israel and India.

Download

caprotec bioanalytics and Syngenta announce research collaboration

Berlin, Germany, August 12, 2013 – caprotec bioanalytics GmbH and Syngenta International AG announced today a joint research agreement in which Syngenta will gain access to caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology. The companies will work together to profile the interactions of one of Syngenta’s novel active compounds with the proteome in its relevant plant biological system. caprotec’s platform allows an unbiased evaluation of the interactions of small molecules with protein mixtures in a targeted and directed manner, thereby facilitating the identification and elucidation of tractable targets as well as accelerating the development of promising leads.

Download

caprotec bioanalytics and Bayer CropScience Announce Second Collaborative Research Agreement

Berlin, Germany, July 22, 2013 – caprotec bioanalytics GmbH and Bayer CropScience announced today that they have entered a second research collaboration to identify and elucidate a tractable agrochemical target using caprotec’s proprietary Capture Compound Mass Spectrometry technology (CCMS).

Download

caprotec bioanalytics GmbH appoints Dr Jonathan Turner as Managing Director and Chief Executive Officer

Berlin, Germany, October 18, 2012 – caprotec bioanalytics GmbH announces a restructuring of its senior management and the appointment of Dr Jonathan Turner to the position of Managing Director and Chief Executive Officer. Prior to joining caprotec, Dr Turner held senior management positions in the international pharmaceutical industry. Professor Hubert Koester, founder of the company and its previous Chief Executive Officer has relinquished that post and assumes responsibility for scientific strategy and technology development as Acting CSO and Chairman of the Scientific Advisory Board.

Download

caprotec bioanalytics Announces Further Patent Protection Of Its CCMS Technology

Berlin, Germany, February 8, 2012 - caprotec bioanalytics GmbH announced today the issuance of patents in the US, Japan, Canada, Australia and Israel related to methods and composition of matter of its proprietary Capture Compound Mass Spectrometry (CCMS) technology.

Download

caprotec bioanalytics Discovers Novel Drug-Protein Interactions of Three Anti-Cancer Drugs Using CCMS Technology

Berlin, Germany and Burlington, MA, December 8, 2011 - caprotec bioanalytics GmbH announced today the discovery of previously unknown specific drug-protein interactions for several anti-cancer drugs and the identification of potential novel co-targets of the drug molecules through the use of company's CCMS technology. These scientific findings are published in peer-reviewed articles in Journal of Proteomics, Proteomics and Journal of Biomedicine and Biotechnology.

Download

caprotec bioanalytics Announces Collaborative Research Agreement With Bayer CropScience

Berlin, Germany and Burlington, MA, December 6, 2011 - caprotec bioanalytics GmbH announced today that it has initiated a research collaboration with Bayer CropScience. Under the collaborative research agreement, caprotec will use its proprietary CCMS (Capture Compound Mass Spectrometry) technology to profile the interactions of one of Bayer CropScience's undisclosed new active ingredients in the relevant biological system.

Download

caprotec bioanalytics GmbH Appoints Marc Voigt as Managing Director, Chief Financial Officer and Chief Operating Officer

Berlin, Germany and Burlington, MA, July 12, 2011 - caprotec bioanalytics GmbH announced today the appointment of Marc Voigt as Managing Director, Chief Financial Officer and Chief Operating Officer.

Download

caprotec bioanalytics Increases Series B Financing in Second Closing to Euro 5 Million

Berlin, Germany and Burlington, MA, May 9, 2011 - caprotec bioanalytics GmbH, a  privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry (CCMS) platform technology for analyzing small molecule – protein
interactions, today announced a second closing of Euro 1 million to its Series B funding, bringing the total for the round to Euro 5 million in equity. The capital increase was fully subscribed by LBBW Venture Capital GmbH, Stuttgart, joining existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.

Download

caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology

Berlin, Germany and Burlington, MA, February 28, 2011 - caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

Download

caprotec bioanalytics GmbH Appoints Prof. Dr. Rainer Metternich as Managing Director, Chief Officer and Chief Operating Officer

Berlin, Germany and Burlington, MA, October 4, 2010 - caprotec bioanalytics GmbH announced today the appointment of Prof. Dr. Rainer Metternich as Managing Director, Chief Business Officer and Chief Operating Officer of the company. Prior joining caprotec, Prof. Metternich held senior leadership positions at Merck & Co., Schering AG and Novartis.

Download

caprotec bioanalytics Announces Commercial Launch of Three New caproKits™ For Applications in Functional Proteomics and Drug Development

Berlin, Germany and Burlington, MA, Sepember 30, 2010 - caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits™, enabling the discovery, identification and characterization of proteins for applications in functional proteomics and drug development.

Download

caprotec bioanalytics announces the successful completion of a collaborative research project with Roche

Berlin, Germany and Burlington, MA, June 28, 2010 - caprotec bioanalytics GmbH announced today that it has succesfully completed a research collaboration with F. Hoffmann-La Roche, Basel, Switzerland. Under the collaboration research agreement, caprotec used its proprietary CCMS (Capture Compound Mass Spectrometry) technology to analyze the binding characteristics and interaction of one undisclosed drug candidate with its human target proteins.

Download

caprotec bioanalytics Completes Series B Financing Round of EUR 4 Million

Berlin, Germany and Burlington, MA, May 13, 2010 - caprotec bioanalytics GmbH today announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company´s proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.

Download

caprotec bioanalytics Announces Commercial Launch Of Three New caproKits™ For Applications In Proteomics And Drug Development

Berlin, Germany and Burlington, MA, January 26, 2010 - caprotec bioanalytics GmbH anounced today the commercial launch of three new caporKits™, enabling the discovery, identification and characterization of proteins belonging to the group of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

Download

Germany-based caprotec bioanalytics opens US Subsidiary in Burlington, Massachusetts; Appoints President

Burlington, MA, and Berlin, Germany, November 19, 2009 - caprotec bioanalytics GmbH ammounced today the opening of its US subsidiary based in Burlington, MA. caprotec Inc. will be responsible for North American sales, marketing and support of caprotec´s proprietary Capture Compound Mass Spectrometry (CCMS) technology and its related products.

Download

caprotec bioanalytics announces launch of new Stauro caproKit™ for signal transduction research and drug development

Berlin, Germany, May 13, 2009 - caprotec bioanalytics GmbH announced today the commercial launch of its Stauro caproKit™, enabling the discovery, identification and characterization of proteins interacting with staurosporine.

Download

caprotec bioanalytics announces the appointment of Funakoshi as distributor for its products on the Japanese market

Berlin, Germany, February 09, 2009 - caprotec bioanalytics GmbH announced today that they entered into an exclusive distributorship agreement with Funakoshi Co. Ltd. for the marketing and sales of caprotec´s research products in the country of Japan.

Download

caprotec bioanalytics announces launch of new products for research and drug development

Berlin, Germany, January 19, 2009 - caprotec bioanalytics GmbH announced today that they completed the commercial launch of their first two caproKits™.

Download

caprotec bioanalytics awarded 0,6 m € grant for research and development

Berlin, Germany, December 15, 2008 – caprotec bioanalytics GmbH announced today that they won a grant of up to 0,6 m € over a period of 2 years.

Download

caprotec bioanalytics adds two patents to its significant patent estate

Berlin, Germany, December 2, 2008 – caprotec bioanalytics GmbH announced today that the Canadian Patent Office hase granted two Canadian patents covering the company's revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

Download

caprotec bioanalytics and Merck KGaA Sign Collaboration Agreement

Berlin, Germany, May 28, 2008 – caprotec bioanalytics GmbH announced today that they have signed a collaboration agreement with Merck KGaA acting for its division Merck Serono.

Download

caprotec bioanalytics GmbH Appoints Dr. Mathias Grote as Chief Financial and Chief Operating Officer

Berlin, Germany, March 13, 2008 – caprotec bioanalytics GmbH announced today the appointment of Dr. Mathias Grote as Chief Financial Officer and Chief Operating Officer of the Company.

Download

Life Science Startup caprotec bioanalytics Receives Additional Venture Capital Funding

Berlin, Germany, January 10, 2008 – caprotec bioanalytics GmbH receives a total of EUR 6 million ($8.8M) in two rounds of financing.

Download

caprotec bioanalytics obtains € 4.5M (ca. $6.5M) Startup financing

Berlin, Germany, November 22, 2007 – caprotec bioanalytics GmbH has obtained capital investments.

Download